SEATTLE, April 25, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported analyses of Phase 2 and Phase 3 clinical data showing the favorable impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement (ILR). OMS302, which contains a mydriatic (pupil-dilating) agent and an anti-inflammatory agent, is the Company's product being developed for use during ILR, including cataract surgery and refractive lens exchange. These analyses were presented on April 21 at the Annual American Society of Cataract and Refractive Surgery (ASCRS) and American Society of Ophthalmic Administrators (ASOA) Symposium and Congress in San Francisco.
The clinical data presented at the ASCRS meeting show that, in the setting of all treatment- and control-group patients receiving standard-of-care preoperative mydriatic topical drops, OMS302 reduces the occurrence of pupil constriction of 2.5 mm or more and the incidence of the pupil constricting to less than 6 mm in diameter throughout surgery. These two measures are widely recognized by ophthalmologic surgeons as important for successful ILR procedures.
"Intraoperative miosis is a challenge to all lens replacement procedures, increasing both surgical time and the risk of an unsuccessful outcome," stated Eric B. Donnenfeld, M.D., clinical professor of ophthalmology at New York University and newly elected president of the ASCRS. "These data show that OMS302 successfully addresses this challenge. Given the well-recognized need for a product like OMS302 in lens replacement procedures, I expect that it will be widely and rapidly adopted by ophthalmologic surgeons."
"The strong reception that OMS302 received from the thought leaders at the ASCRS and ASOA Congress was gratifying," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "When presented with the data package for OMS302, ophthalmologic surgeons uniformly appreciate the product's benefits and expect that it will become an important part of standard practice for intraocular lens replacement. We look forward to making OMS302 available to surgeons and their patients."About Omeros' OMS302 Program OMS302 is Omeros' product being developed for use during intraocular lens replacement (ILR), including cataract surgery and refractive lens exchange. OMS302 is a proprietary combination of the mydriatic (pupil dilating) agent phenylephrine and the anti-inflammatory agent ketorolac. Omeros recently completed its successful OMS302 Phase 3 clinical program and expects to submit a New Drug Application to the U.S. Food and Drug Administration this quarter and a Marketing Authorization Application to the European Medicines Agency in mid-2013.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV